Ibuprofen transdermal ethosomal gel: Characterization and efficiency in animal models

Journal of Biomedical Nanotechnology

Volumn 6, Issue 5, 2010, Pages 569-576

  Shumilov, Margarita ^a   Bercovich, Ronny ^a   Duchi, Shaher ^a   Ainbinder, Denize ^a   Touitou, Elka ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Analgesic; Animal Models; Antipyretic; Ethosome; Ibuprofen; Transdermal

Indexed keywords

ANALGESIC; ANIMAL MODELS; ANTIPYRETIC; ETHOSOME; IBUPROFEN; TRANSDERMAL;

BIOCHEMISTRY; GELS; NANOSYSTEMS; NORMAL DISTRIBUTION;

ANIMALS;

ETHOSOME; IBUPROFEN; NANOCARRIER; UNCLASSIFIED DRUG; ANALGESIC AGENT; ANTIPYRETIC AGENT; LIPOSOME;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPYRETIC ACTIVITY; ARTICLE; BODY TEMPERATURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SAFETY; FEVER; GEL; HISTOLOGY; LIPID VESICLE; MALE; NONHUMAN; RAT; ANIMAL; CHEMISTRY; DISEASE MODEL; HUMAN; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; PAIN; TREATMENT OUTCOME; WISTAR RAT;

ADMINISTRATION, CUTANEOUS; ANALGESICS, NON-NARCOTIC; ANIMALS; ANTIPYRETICS; DISEASE MODELS, ANIMAL; FEVER; GELS; HUMANS; IBUPROFEN; MALE; PAIN; RATS; RATS, WISTAR; TREATMENT OUTCOME; UNILAMELLAR LIPOSOMES;

EID: 79953145521     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2010.1153     Document Type: Article

References (21)

1. K. D. Rainsford, Discovery, mechanisms of action and safety of ibuprofen. Int. J. Clin. Pract. Suppl. 135, 3 (2003).
2. K. D. Rainsford, Ibuprofen: Pharmacology, efficacy and safety. Inflammopharmacology 17, 275 (2009).
3. J. N. van den Anker, Use of ibuprofen in paediatric populations. J. R. Soc. Med. 100, 18 (2007).
4. E. Touitou, N. Dayan, L. Bergelson, B. Godin, and M. Eliaz, Ethosomes-novel vesicular carriers for enhanced delivery: Characterization and skin penetration properties. J. Controlled Release 65, 403 (2000).
5. E. Touitou, Compositions for applying active substances to or through the skin, US Patent 5,716,638 (1998).
6. B. Godin and E. Touitou, Mechanism of bacitracin permeation enhancement through the skin and cellular membranes from an ethosomal carrier, J. Controlled Release 94, 365 (2004).
7. M. Lodzki, B. Godin, L. Rakou, R. Mechoulam, R. Gallily, and E. Touitou, Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model. J. Controlled Release 93, 377 (2003).
8. D. Ainbinder and E. Touitou, Testosterone ethosomes for enhanced transdermal delivery. Drug. Deliv. 12, 297 (2005).
9. M. Shumilov and E. Touitou, Buspirone transdermal administration for menopausal syndromes, in vitro and in animal model studies. Int. J. Pharm. 387, 26 (2010).
10. E. Horwitz, S. Pisanty, R. Czerninsky, M. Heiser, E. Eliav, and E. Touitou, A clinical evaluation of a novel liposomal carrier for acyclovir in the topical treatment of recurrent herpes labialis. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. 88, 700 (1999).
11. E. Touitou, B. Godin, and C. Weiss, Enhanced delivery of drugs into and across the skin by ethosomal carriers. Drug Dev. Res. 50, 406 (2000).
12. B. Godin, E. Touitou, E. Rubinstein, A. Athamna, and M. Athamna, A new approach for treatment of deep skin infections by an ethosomal antibiotic preparation: An in vivo study, J. Antimicrob. Chemother. 55, 989 (2005).
13. E. Touitou, B. Godin, M. Shumilov, N. Bishouty, D. Ainbinder, R. Shouval, A. Ingber, and V. Leibovici, Efficacy and tolerability of clindamycin phosphate and salicylic acid gel in the treatment of mild to moderate acne vulgaris. J. Eur. Acad. Dermatol. Venereol 22, 629 (2008).
14. A. M. Rustam, Assay of ibuprofen in human plasma by rapid and sensitive reversed-phase high-performance liquid chromatography: Application to a single dose pharmacokinetics study. J. Chromatogr. Sci. 29, 16 (1991).
15. L. M. Lichtenberger, J. J. Romero, W. M. J. De Ruijter, F. Behbod, R. Darling, A. Q. Ashraf, and S. K. Sanduja, Phosphatidylcholine association increases the anti-inflammatory and analgesic activity of ibuprofen in acute and chronic rodent models of joint inflammation: Relationship to alterations in bioavailability and cyclooxygenase-inhibitory potency. J. Pharmacol. Exp. Ther. 298, 279 (2001).
16. J. J. Loux, P. D. Depalma, and S. L. Yankell, Antipyretic testing of aspirin in rats. Toxicol. Appl. Pharmacol. 22, 672 (1972).
17. A. S. Bhat, S. K. Tandan, D. Kumar, V. Krishna, and V. R. Prakash, Interaction between inhibitors of inducible nitric oxide synthase and cyclooxygenase in Brewer's yeast induced pyrexia in mice: An isobolographic study. Eur. J. Pharmacol. 511, 137 (2005).
18. P. Archana, S. K. Tandan, S. Chandra, and J. Lal, Antipyretic and analgesic activities of caesalpinia bonducella seed kernel extract. Phytother. Res. 19, 376 (2005).
19. F. E. D'Amour and D. L. Smith, A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 72, 74 (1941).
20. A. Dogrul, S. E. Gulmez, M. S. Deveci, H. Gul, M. H. Ossipov, F. Porreca, and F. C. Tulunay, The local antinociceptive actions of nonsteroidal anti-inflammatory drugs in the mouse radiant heat tail-flick test. Anesth. Analg. 4, 927 (2007).
21. B. Chertin, E. Touitou, B. Godin, A. Pollack, D. Shemesh, and A. Farkas, The efficiency of topical treatment with ethosomal PGE1 formulation in erectile dysfunction patients, Proceedings Annual Meeting of Israeli Urological Association, Eilat, Israel (2006).